Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Intensive Uric Acid Lowering Therapy With RDEA3170 (Verinurad) and Febuxostat in Patients With Albuminuria

NCT03118739 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03118739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03118739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Intensive Uric Acid Lowering Therapy With RDEA3170 (Verinurad) and Febuxostat in Patients With Albuminuria
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
May 18, 2017
Completion date
August 13, 2018
Enrollment
60 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

albuminuria, hyperuricemia, type 2 diabetes